Oceana Therapeutics, Inc.

Oceana Therapeutics, Inc.

Oceana Therapeutics, Inc.

Overview
Date Founded

2008

Headquarters

2035 Lincoln Highway,Suite 2150,Edison, NJ 08817

Type of Company

Private

Industries

Pharmaceuticals
Medical Products & Equipment

Company Description

Oceana Therapeutics, Inc. manufactures pharmaceuticals and medical devices. It develops and commercializes therapeutics with a focus on colorectal, gastroenterology, and urological diseases. The firm provides Deflux that is used for the treatment of Vesicoureteral reflux, urological conditions and Solesta which is used for the treatment of fecal incontinence. The company was founded in 2008 and is headquartered in Edison, NJ.

Executives & Employees

Vice President-Finance & Controller

Senior Vice President-Marketing

Board of Directors

Co-Founder at Onkos Surgical, Inc.

Chief Executive Officer & Director at Bimeda Holdings Plc

Paths to Oceana Therapeutics, Inc.
Potential Connections via
Relationship Science
You
Oceana Therapeutics, Inc.
Recent Transactions
Details Hidden

Salix Pharmaceuticals Ltd. purchases Oceana Therapeutics, Inc.

Details Hidden

Oceana Therapeutics, Inc. raised money in a private placement transaction

Transaction Advisors
Legal Advisor

Advised onSalix Pharmaceuticals Ltd. purchases Oceana Therapeutics, Inc.

Investment Advisor

Advised onSalix Pharmaceuticals Ltd. purchases Oceana Therapeutics, Inc.

Investors
Details Hidden

Frazier Management provides venture capital to invests in developing and commercializing novel therapeutics and and growth equity capital invests in healthcare services, pharmaceutical services, medical products, and related sectors. with primary focus on The firm invests across all stages of development.The firm's venture capital strategy focuses on all stages of biopharmaceutical and medical device companies including seed, early, mid, late, PIPEs and public. Their biopharmaceutical investment strategy focuses on companies that are developing novel therapeutics. They seek to identify early-stage companies that can use the firm's capital to move their products through clinical trials to achieve clinical proof of concept. Frazier works with a variety of types of companies including concept-stage, preclinical drug leads, clinical candidates and marketed products. The therapeutic modality also varies from small molecule to biologic. Frazier's medical device strategy focuses on companies with innovative technologies that address significant unmet clinical needs in large market segments.When considering a venture capital investment, Frazier looks for companies with exceptional management teams and capital efficient business models. They seek companies that are building their product portfolio through (1) novel targets or device-based approaches to existing targets which are significantly differentiated (2) paradigm-shifting therapeutic or device platforms to develop multiple products or (3) repositioning or in-licensing of existing drugs which are known to be safe and may have applications in other indications. The firm prefers to invest in products with large addressable markets in therapeutic areas that are supported by healthcare professionals who are open to innovative therapies. Frazier looks for therapeutic drug products that are close to or already in the clinic. They seek medical devices with moderate development risk that can rapidly generate clinical proof of principle and/or can be launched commercially within a reasonable time frame. Companies should have a clear path to regulatory approval and positive reimbursement decisions.Frazier also seeks to invest in cash-generating, growth-oriented healthcare companies. Types of investments include: acquisitions, recapitalizations, buyouts, build-ups and growth capital. They focus on the healthcare services, medical devices and supplies, specialty pharmaceutical and information technology-enabled services sectors. Investments typically range from $15 million to $50 million. The firm looks for companies with experienced management teams, attractive free cash flow margins, meaningful organic growth with the potential for consolidation opportunities, leading and defensible market positions, a predictable reimbursement environment and demonstrable customer loyalty.

Details Hidden

Operating Partner at 1315 Capital LLC

Details Hidden

Venture Partner at Signet Healthcare Partners LLC

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Oceana Therapeutics, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Oceana Therapeutics, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Oceana Therapeutics, Inc..
  • be_ixf; php_sdk; php_sdk_1.4.15
  • https://relationshipscience.com/organization/oceana-therapeutics-inc-977377
  • https://relationshipscience.com/organization/oceana-therapeutics-inc-977377